{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:16:05Z","timestamp":1793643365245,"version":"4.5.1"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018551","name":"Science and Technology Innovation Talents in Universities of Henan Province","doi-asserted-by":"publisher","award":["SBGJ202402041"],"award-info":[{"award-number":["SBGJ202402041"]}],"id":[{"id":"10.13039\/501100018551","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.critrevonc.2025.104752","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:40:39Z","timestamp":1746186039000},"page":"104752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Recent development in bispecific antibody immunotherapy for hematological malignancies"],"prefix":"10.1016","volume":"212","author":[{"given":"Lijie","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.critrevonc.2025.104752_bib1","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104752_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.omto.2019.02.004","article-title":"Single-chain variable fragment-based bispecific antibodies: hitting two targets with one sophisticated arrow","volume":"14","author":"Ahamadi-Fesharaki","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.critrevonc.2025.104752_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.omto.2019.02.004","article-title":"Single-chain variable fragment-based bispecific antibodies: hitting two targets with one sophisticated arrow","volume":"14","author":"Ahamadi-Fesharaki","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.critrevonc.2025.104752_bib4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immunetargeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104752_bib5","first-page":"465","article-title":"BiTEs, DARTS, BiKEs and TriKEs-are antibody based therapies changing the future treatment of AML?","volume":"11","author":"Allen","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104752_bib6","unstructured":"Anon, May 2023, the FDA granted accelerated approval to epcoritamab for treatment of adult patients with R\/R DLBCL, not otherwise specified, including DLBCL arising from indolent lymphoma, and hig."},{"key":"10.1016\/j.critrevonc.2025.104752_bib7","unstructured":"Anon, (2025) \u3008https:\/\/www.drugs.com\/newdrugs\/fda-approves-blincyto-blinatumomab-cd19-positive-philadelphia-chromosome-negative-b-all-6298.html\u3009."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-Cell lymphoma (DLBCL)","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2025.104752_bib9","article-title":"CAMMA 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Bachier","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104752_bib10","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40364-024-00610-z","article-title":"Harnessing natural killer cells for refractory\/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective","volume":"12","author":"Bakhtiyaridovvombaygi","year":"2024","journal-title":"Biomark. Res."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104752_bib12","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104752_bib13","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104752_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib15","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2023-180246","article-title":"Epcoritamab SC + GemOx leads to high complete metabolic response rates in patients with relapsed\/refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant: updated results from epcore NHL-2","volume":"142","author":"Brody","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104752_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104752_bib17","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-hodgkin lymphomas: extended follow-up of a phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2021-153355","article-title":"A phase 1 dose escalation study of igm-2323, a novel anti-CD20 x anti-CD3 IgM T cell engager (TCE) in patients with advanced B-Cell malignancies","volume":"138","author":"Budde","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104752_bib19","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104752_bib20","doi-asserted-by":"crossref","first-page":"343e57","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"Carter","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104752_bib21","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104752_bib22","doi-asserted-by":"crossref","first-page":"965e82","DOI":"10.1080\/14712598.2022.2072209","article-title":"Bispecific antibodies for immune cell retargeting against cancer","volume":"22","author":"Chen","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104752_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/antib8040055","article-title":"Antibody Structure and Function: The Basis for Engineering Therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.critrevonc.2025.104752_bib24","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood-2018-99-118425","article-title":"Anti-BCMA BiTE\u00ae AMG 701 potently induces specific T cell lysis of human multiple myeloma (MM) cells and immunomodulation in the bone marrow microenvironment","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104752_bib25","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib26","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1182\/blood-2023-181602","article-title":"Odronextamab demonstrates durable complete responses in patients with diffuse large B-Cell lymphoma (DLBCL) progressing after CAR-T therapy: outcomes from the ELM-1 study","volume":"142","author":"Crombie","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104752_bib27","first-page":"3e17","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"Dahle\u00b4n","year":"2018","journal-title":"Ther. Adv. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/hematology.2023000508","article-title":"Bispecific antibody therapies","volume":"2023","author":"de Assis","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104752_bib29","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104752_bib30","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transpl. Cell Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104752_bib31","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s12325-024-02797-x","article-title":"Comparative efficacy of talquetamab vs. current treatments in the LocoMMotion and MoMMent studies in patients with triple-class-exposed relapsed\/refractory multiple myeloma","volume":"41","author":"Einsele","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2025.104752_bib32","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.3390\/ijms22115632","article-title":"Principles and current clinical landscape of multispecific antibodies against cancer","volume":"22","author":"Elshiaty","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104752_bib33","article-title":"DuoBody-CD3xCD20 induces potent T-cellmediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelbertsa","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2025.104752_bib34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104752_bib35","unstructured":"FDA. Bispecific antibody development programs guidance for industry. U.S. Food & Drug Administration; May 24, 2021. Available from:\u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bispecific-antibody-development-programs-guidance-industry\u3009."},{"key":"10.1016\/j.critrevonc.2025.104752_bib36","unstructured":"FDA June 2023, the FDA granted accelerated approval to glofitamab for the treatment of adult patients with R\/R DLBCL, not otherwise specified, or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy."},{"key":"10.1016\/j.critrevonc.2025.104752_bib37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to improve NK Cell-mediated targeting of tumor cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104752_bib38","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jha2.69","article-title":"Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed\/refractory multiple myeloma","volume":"1","author":"Foureau","year":"2020","journal-title":"EJHaem"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104752_bib40","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1182\/bloodadvances.2023011130","article-title":"Blinatumomab consolidation post-autologous stem cell transplantation in patients with diffuse large B-cell lymphoma","volume":"8","author":"Ghobadi","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104752_bib41","doi-asserted-by":"crossref","first-page":"74e103","DOI":"10.1016\/j.xphs.2019.05.031","article-title":"Considerations for the design of antibodybased therapeutics","volume":"109","author":"Goulet","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104752_bib42","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/s41388-021-01811-8","article-title":"Antibody-based cancer therapy","volume":"40","author":"Goydel","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2025.104752_bib43","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2022-162738","article-title":"Elranatamab in combination with daratumumab for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 3 magnetismm-5 study safety lead-in cohort","volume":"140","author":"Grosicki","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104752_bib44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/14712598.2024.2333793","article-title":"Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting","volume":"24","author":"Han","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104752_bib45","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2023-173951","article-title":"Glofitamab monotherapy in relapsed or refractory large B-Cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-Cell therapy and by baseline total metabolic tumor volume","volume":"142","author":"Hutchings","year":"2023","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104752_bib47","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10306","key":"10.1016\/j.critrevonc.2025.104752_bib48","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104752_bib49","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib50","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104752_bib51","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/ajh.27463","article-title":"A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia","volume":"99","author":"Jen","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104752_bib52","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104752_bib53","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"MAbs"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104752_bib54","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/10428194.2022.2064981","article-title":"Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL","volume":"63","author":"Katz","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104752_bib55","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE\u00ae) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2025.104752_bib56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","article-title":"Engineering therapeutic bispecific antibodies using CrossMab technology","volume":"154","author":"Klein","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.critrevonc.2025.104752_bib57","doi-asserted-by":"crossref","first-page":"838e47","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.critrevonc.2025.104752_bib58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104752_bib59","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000539391","volume":"47","author":"Lang","year":"2024","journal-title":"Oncol. Res Treat."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib60","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104752_bib61","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104752_bib62","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14712598.2023.2273276","article-title":"Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting","volume":"23","author":"Li","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib63","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2023-179887","article-title":"Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: first data disclosure from the epcore NHL-1 follicular lymphoma dose-expansion cohort","volume":"142","author":"Linton","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104752_bib64","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-024-01597-8","article-title":"Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial","volume":"17","author":"Lu","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104752_bib66","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.clml.2023.11.001","article-title":"Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase II MajesTEC-1 study","volume":"24","author":"Martin","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104752_bib67","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete Hematologic and Molecular Response in Adult Patients With Relapsed\/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104752_bib68","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab safety profile in patients with relapsed\/refractory B-cell non-hodgkin lymphoma: clinical management experience from a pivotal phase I\/II trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.104752_bib69","doi-asserted-by":"crossref","unstructured":"Mateos M.V., Bahlis N.J., Spencer A., Kaedbey R., Rodr\u00edguez-Otero P., Harrison S., et al. P946: tocilizumab pre-treatment significantly reduces the incidence of cytokine release syndrome in patients with relapsed\/refractory multiple myeloma (rrmm) who receive cevostamab. Lid - e75458a8. (2572-9241 (electronic)). HemaSphere (2023).","DOI":"10.1097\/01.HS9.0000970688.75458.a8"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib70","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/blood-2023-180089","article-title":"Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5","volume":"142","author":"Mazza","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104752_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008213","article-title":"Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL","volume":"12","author":"Mikhailova","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104752_bib73","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","article-title":"A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma","volume":"65","author":"Mol","year":"2024","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104752_bib74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17474086.2024.2353751","article-title":"Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed\/refractory multiple myeloma","volume":"17","author":"Moore","year":"2024","journal-title":"Expert Rev. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104752_bib75","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","article-title":"Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective locommotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma","volume":"40","author":"Moreau","year":"2023","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104752_bib76","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib77","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1182\/blood-2023-174250","article-title":"AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)","volume":"142","author":"Moskowitz","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib78","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2023-172980","article-title":"Innate Cell Engager (ICE\u00ae) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results","volume":"142","author":"Nieto","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104752_bib79","unstructured":"NMPA. The technical guidelines for clinical research and development of bispecific antibody antineoplastic drugs. Center for Drug Evaluation, NMPA; November 14, 2022. Available from: \u3008https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/e9e97adf7fd91fff6c49afac1320d233\u3009."},{"key":"10.1016\/j.critrevonc.2025.104752_bib80","first-page":"588e94","article-title":"The coming of age of engineered multivalent antibodies","volume":"20","author":"Nun\u02dcez-Prado","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104752_bib81","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11899-024-00740-z","article-title":"Management of toxicities associated with BCMA, GPRC5D, and FcRH5-targeting bispecific antibodies in multiple myeloma","volume":"19","author":"Pan","year":"2024","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.critrevonc.2025.104752_bib82","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","article-title":"Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma","volume":"18","author":"Panowski","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib84","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1182\/blood-2022-159586","article-title":"A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with Relapsed\/ Refractory Non-Hodgkin\u2019s lymphoma: recommended dose Safety\/Efficacy update and escalation exposure-response analysis","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104752_bib85","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104752_bib86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.critrevonc.2025.104752_bib87","article-title":"Long-term efficacy and safety results from the phase 1\/2 monumental-1 study of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","author":"Rasche","year":"2024","journal-title":"HemaSphere"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104752_bib88","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","article-title":"Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia","volume":"7","author":"Ravandi","year":"2023","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104752_bib89","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104752_bib90","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecifc TandAb (CD30\/CD16A) efciently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.critrevonc.2025.104752_bib91","doi-asserted-by":"crossref","first-page":"617e21","DOI":"10.1093\/protein\/9.7.617","article-title":"Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104752_bib92","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104752_bib93","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104752_bib94","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104752_bib95","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/03007995.2024.2387183","article-title":"Real-world experience with clinical management of talquetamab in relapsed\/refractory multiple myeloma: a qualitative study of US healthcare providers","volume":"40","author":"Schinke","year":"2024","journal-title":"Curr. Med Res Opin."},{"key":"10.1016\/j.critrevonc.2025.104752_bib96","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104752_bib97","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-019-02725-3","article-title":"A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration","volume":"476","author":"Sch\u00fcrch","year":"2019","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2025.104752_bib98","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283802","article-title":"Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma","author":"Song","year":"2023","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104752_bib99","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104752_bib101","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell-engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104752_bib102","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104752_bib103","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"10301","key":"10.1016\/j.critrevonc.2025.104752_bib104","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104752_bib105","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104752_bib106","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2025.104752_bib107","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood-2023-180935","article-title":"Epcoritamab SC + R-Mini-CHOP leads to high complete metabolic response rates in patients with previously untreated diffuse large B-cell lymphoma ineligible for full-dose R-CHOP: first disclosure from arm 8 of the epcore NHL-2 trial","volume":"142","author":"Vermaat","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104752_bib108","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104752_bib109","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/13543784.2018.1452911","article-title":"Investigational CD33-targeted therapeutics for acute myeloid leukemia","volume":"27","author":"Walter","year":"2018","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.critrevonc.2025.104752_bib110","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114291","article-title":"The state of the art of bispecific antibodies for treating human malignancies","volume":"13","author":"Wang","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.critrevonc.2025.104752_bib111","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.critrevonc.2025.104752_bib112","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","article-title":"AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy","volume":"8","author":"Wu","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104752_bib113","doi-asserted-by":"crossref","first-page":"470e82","DOI":"10.1080\/19420862.2015.1022694","article-title":"Fab-based bispecific antibody formats with robust biophysical properties and biological activity","volume":"7","author":"Wu","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.critrevonc.2025.104752_bib114","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40164-021-00250-1","article-title":"Recent advances and challenges of bispecific antibodies in solid tumors","volume":"10","author":"Wu","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104752_bib115","doi-asserted-by":"crossref","first-page":"16e26","DOI":"10.1006\/cimm.2000.1617","article-title":"In vitro characterization of five humanized OKT3 effector function variant antibodies","volume":"200","author":"Xu","year":"2000","journal-title":"Cell Immunol."},{"key":"10.1016\/j.critrevonc.2025.104752_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(24)02002-0","article-title":"Talquetamab versus real-world physician's choice treatment: comparative effectiveness in patients with triple-class exposed relapsed\/refractory multiple myeloma","author":"Ye","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.104752_bib117","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-017-0522-z","article-title":"Recent advances of bispecific antibodies in solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib118","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104752_bib119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"issue":"1-3","key":"10.1016\/j.critrevonc.2025.104752_bib120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/17474086.2023.2298732","article-title":"Comparison of blinatumomab and CAR T-cell therapy in relapsed\/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"17","author":"Zhai","year":"2024","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib121","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104752_bib122","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-024-01611-z","article-title":"Targeting GPRC5D for multiple myeloma therapy","volume":"17","author":"Zhou","year":"2024","journal-title":"J. Hematol. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:15:14Z","timestamp":1752711314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":122,"alternative-id":["S1040842825001404"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104752","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent development in bispecific antibody immunotherapy for hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104752"}}